MedTrace Logo

Liver Injury After COVID-19 Vaccination

NCT05470894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 379

Last updated 2025-03-24

No results posted yet for this study

Summary

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.

Conditions

  • Subjects After COVID-19 Vaccination

Interventions

BIOLOGICAL

Approved COVID-19 vaccine

Vaccination for COVI9-19

Sponsors & Collaborators

  • Tokyo University

    collaborator OTHER

  • Nihon University School of Medicine

    collaborator UNKNOWN

  • Humanity & Health Medical Group Limited

    lead OTHER

Principal Investigators

  • George Lau, MD · Humanity & Health Medical Group

  • Masao Omata, MD, PhD · Tokyo University

  • Tatsuo Kanda, MD, PhD · Nihon University School of Medicine

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Hong Kong
  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05470894 on ClinicalTrials.gov